Latest Breaking News On - Harout semerjian - Page 3 : comparemela.com

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease Single ascending.

GlycoMimetics, Inc. (NASDAQ:GLYC) Q2 2023 Earnings Call Transcript

Operator: Good morning, and thank you for joining the GlycoMimetics, Q2 2023 Earnings Call. At this time all participants are in listen-only mode.

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

Final analysis to be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date; topline results expected by the end of Q2 2024 Prolonged duration of blinded pooled. | June 15, 2023

GlycoMimetics (GLYC) Announces FDA Clearance of Time-based Final Analysis to Phase 3 Study of Uproleselan

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

GlycoMimetics, Inc. today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7,. | May 31, 2023